HLA-A*1101 LMP2 Complex Protein, Human (SSCSSCPLTK, HEK293, His-Avi)

HLA-A*1101as is a key MHCI molecule that presents viral and tumor-derived peptides that direct T cell immune responses against infected or transformed cells. It collaborates with B2M to showcase a diverse peptide library. HLA-A*1101 LMP2 Complex Protein, Human (SSCSSCPLTK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A*1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293 , with C-Avi, C-His labeled tag and SSCSSCPLTK peptide. HLA-A*1101 LMP2 Complex Protein, Human (SSCSSCPLTK, HEK293, His-Avi), has molecular weight of 51-60 kDa.

HLA-A*1101, an antigen-presenting major histocompatibility complex class I (MHCI) molecule, serves a pivotal role in immune responses by presenting predominantly viral and tumor-derived peptides on antigen-presenting cells. This presentation facilitates the recognition of these peptides by the alpha-beta T cell receptor (TCR) on HLA-A-restricted CD8-positive T cells, guiding antigen-specific T cell immune responses aimed at eliminating infected or transformed cells. In collaboration with B2M/beta 2 microglobulin, HLA-A*1101 displays a diverse peptide repertoire, encompassing viral epitopes and tumor-associated antigens. Both the presented peptide and the MHCI molecule contribute to the specificity of antigen recognition, with the peptide determining fine specificity and MHCI residues influencing the MHC restriction of T cells. HLA-A*1101 typically presents intracellular peptide antigens of 8 to 13 amino acids arising from cytosolic proteolysis. It can bind different peptides containing allele-specific binding motifs, primarily defined by anchor residues at positions 2 and 9. Allele-specific motifs characterize distinct peptide repertoires, such as A*01:01, presenting viral epitopes and tumor antigens with a common canonical motif. Notably, HLA-A*1101 fails to present highly immunogenic peptides from EBV latent antigens. For A*11:01, it plays a crucial role in controlling infections, presenting immunodominant epitopes from HIV-1, EBV, and HBV, along with contributing to the immune response against SARS-CoV-2.

Human

HEK293

C-Avi;C-His

AAV53343.1 (G25-T305)&P61769 (I21-M119)&SSCSSCPLTK

3105&567

51-60 kDa

Greater than 95% as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.